Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xoma
Biotech
ObsEva sells off one of 2 remaining assets to stay afloat
Only two months after cutting staff by 70% to focus much of its remaining resources on preterm labor treatment ebopiprant, ObsEva is now selling it.
James Waldron
Nov 22, 2022 7:35am
Agenus sells cut of Incyte, Merck milestone streams
Sep 21, 2018 9:45am
Novartis buys Xoma’s failed IL-1 drug at a knockdown price
Aug 28, 2017 9:33am
Xoma up on broadly positive data, but questions remain
Feb 1, 2017 7:46am
